Fight Against Patent for Hepatitis C Drug That Can Cost €55,000

March 29, 2017

(New Scientist) – A GROUP of charities, led by Médecins Sans Frontières, is fighting to have a drug’s patent revoked by the European Patent Office. Sofosbuvir can cure hepatitis C in just three months, but costs up to €55,000 for a course of treatment. The drug’s patent is held by pharmaceuticals firm Gilead of Foster City, California, giving the company a monopoly over the drug in Europe.